Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.82 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.53 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5671719 | 0.93 | CRHBP (0.72) | CRHBPCRHR2ALDH1A1KDM4EMAPT | |
| SCHEMBL2302918 | 0.85 | CRHBP (0.62) | CRHBPCRHR2ALDH1A1KDM4EMAPT | |
| SCHEMBL4052334 | 0.84 | CRHBP (0.61) | CRHBPCRHR2ALDH1A1KDM4EMAPT | |
| SCHEMBL5671867 | 0.82 | CRHBP (0.61) | CRHBPCRHR2ALDH1A1KDM4EMAPT | |
| SCHEMBL27677805 | 0.81 | CRHBP (0.56) | CRHBPCRHR2ALDH1A1KDM4EMAPT | |
| SCHEMBL14125069 | 0.81 | CRHBP (0.57) | CRHBPCRHR2ALDH1A1KDM4EMAPT | |
| SCHEMBL5671851 | 0.80 | POLB (0.60) | CRHBPCRHR2TSHRLMNAMAPK1 | |
| SCHEMBL182493 | 0.80 | MAPT (0.62) | CRHBPCRHR2ALDH1A1KDM4EMAPT | |
| SCHEMBL1641929 | 0.79 | CRHBP (0.61) | CRHBPCRHR2ALDH1A1KDM4ETSHR | |
| SCHEMBL15363131 | 0.78 | ALDH1A1 (0.70) | CRHBPCRHR2ALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227567-A1 | METHODS OF TREATING P38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-10 | — | — | US | disclosed |
| EP-1669071-B1 | Pyrrolotriazine inhibitors of kinases | BRISTOL MYERS SQUIBB CO (US) | 2009-07-22 | — | — | EP | disclosed |
| US-7244733-B2 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-17 | — | — | US | disclosed |
| US-7112675-B2 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-26 | — | — | US | disclosed |
| US-7094791-B2 | Derivatives of 3-hydroxy-pyrrole-2,4-dicarboxylic acid and uses thereof | AVALON PHARMACEUTICALS, INC. (US) | 2006-08-22 | — | — | US | disclosed |
| US-20060128709-A1 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY | 2006-06-15 | — | — | US | disclosed |
| EP-1669071-A1 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1363910-B1 | METHODS OF TREATING P38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-03-01 | — | — | EP | disclosed |
| EP-1183033-B1 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL MYERS SQUIBB CO (US) | 2006-03-01 | — | — | EP | disclosed |
| US-20060004007-A1 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
| WO-2005011675-A1 | DERIVATIVES OF 3-HYDROXY-PYRROLE-2,4-DICARBOXYLIC ACID AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2005-02-10 | — | — | WO | disclosed |
| US-20050026991-A1 | Derivatives of 3-hydroxy-pyrrole-2,4-dicarboxylic acid and uses thereof | CLINICAL DATA, INC. | 2005-02-03 | — | — | US | disclosed |
| US-20040229877-A1 | Methods of treating p38 kinase-associated conditions with pyrrolotriazine compounds | LEFTHERIS KATERINA (US) | 2004-11-18 | — | — | US | disclosed |
| US-6670357-B2 | Antiinflammatory agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-30 | — | — | US | disclosed |
| EP-1363910-A2 | METHODS OF TREATING P38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20030069244-A1 | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-10 | — | — | US | disclosed |
| EP-1183033-A4 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL MYERS SQUIBB CO (US) | 2002-07-17 | — | — | EP | disclosed |
| WO-2002040486-A2 | METHODS OF TREATING p38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-05-23 | — | — | WO | disclosed |
| EP-1183033-A1 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000071129-A1 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069244-A1 | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors | MAPK1, MAPK3, MAPK6 | CRHBP 776/4885CRHR2 157/4885ALDH1A1 3836/4885 |
| US-20090227567-A1 | METHODS OF TREATING P38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | MAP3K5, MAPK1, MAPKAPK5 | CRHBP 772/4885CRHR2 107/4885ALDH1A1 4117/4885 |
| US-20060128709-A1 | Pyrrolotriazine inhibitors of kinases | FGFR1, FGFR2, ERBB2 | CRHBP 3479/4885CRHR2 1767/4885ALDH1A1 1255/4885 |
| US-20060004007-A1 | Pyrrolotriazine inhibitors of kinases | FGFR1, FGFR2, ERBB2 | CRHBP 3479/4885CRHR2 1767/4885ALDH1A1 1255/4885 |
| US-20040229877-A1 | Methods of treating p38 kinase-associated conditions with pyrrolotriazine compounds | MAPK1, MAPK6, MAPK3 | CRHBP 630/4885CRHR2 70/4885ALDH1A1 3580/4885 |
| US-20050026991-A1 | Derivatives of 3-hydroxy-pyrrole-2,4-dicarboxylic acid and uses thereof | HPGDS, PHGDH, PDHA2 | CRHBP 1490/4885CRHR2 2299/4885ALDH1A1 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.